Last reviewed · How we verify
ASA-withdrawn group — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
ASA-withdrawn group (ASA-withdrawn group) — Hospital Universitari Vall d'Hebron Research Institute. ASA-withdrawn group refers to a cohort of patients who discontinued aspirin therapy, typically studied to assess rebound thrombotic or cardiovascular effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASA-withdrawn group TARGET | ASA-withdrawn group | Hospital Universitari Vall d'Hebron Research Institute | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASA-withdrawn group CI watch — RSS
- ASA-withdrawn group CI watch — Atom
- ASA-withdrawn group CI watch — JSON
- ASA-withdrawn group alone — RSS
Cite this brief
Drug Landscape (2026). ASA-withdrawn group — Competitive Intelligence Brief. https://druglandscape.com/ci/asa-withdrawn-group. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing